Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens.
Josep TaberneroPhilippe L BedardYung-Jue BangMaria VieitoMin-Hee RyuNathalie FagniezMustapha ChadjaaChristine SouffletNina MassonAnas GazzahPublished in: Cancer research communications (2023)
The collective results of this phase I dose-escalation study will inform further studies of tusamitamab ravtansine in patients with solid tumors with CEACAM5 expression, including patients with non-small cell lung cancer.